Investors Double Down on Robotics: ROBO Sees $225M Flow SurgeThe shift toward "physical AI†— the marriage of intelligence and hardware — is fueling a massive surge in both performance and fund flows for the [ROBO Global Robotics and Automation Index ETF (ROBO)]. As AI moves beyond digital chat boxes into physical hardware, the addressable market has exploded, and investors are capitalizing on this growth opportunity in robotics.ROBO's assets under management reached $1.7 billion this week, lifted by a signi ...

Core Viewpoint - Illumina Inc. has seen a rise in its stock price following the announcement of reimbursement for its FDA-approved TruSight Oncology Comprehensive test, which is expected to enhance the adoption of genomic profiling in the U.S. healthcare system [1][2]. Group 1: Reimbursement and Test Impact - The reimbursement from the Centers for Medicare and Medicaid Services (CMS) will be at a rate of $2,989.55 per test, effective January 1 [2]. - The TruSight Oncology Comprehensive test assesses over 500 genes, promoting broader access to precision oncology diagnostics [3]. - Approximately 60% of Illumina's sequencing consumables revenue was attributed to clinical customers last year, indicating significant growth potential [3]. Group 2: Stock Performance and Analyst Insights - Illumina's stock is currently trading 2.65% above its 12-month moving average, with a 2.9% increase over the past year [4]. - The stock carries a Neutral Rating with an average price target of $130.24, and analysts expect a 28% earnings growth, justifying the premium P/E multiple [7]. - Recent analyst actions include a Hold rating from TD Cowen with a target raised to $140.00 and a Buy rating from Guggenheim with a target raised to $144.00 [8]. Group 3: Benzinga Edge Rankings - Illumina scores high on the Benzinga Edge rankings, with a Momentum score of 86.32/100 indicating strong short-term performance, but a low Value score of 18.92/100 suggesting it is trading at a steep premium [9][10]. - The EPS estimate is $1.22, up from $0.95 year-over-year, while the revenue estimate remains at $1.10 billion [8]. Group 4: ETF Impact - Illumina shares were up 2.52% at $145.22, with significant weights in various ETFs, including 3.84% in Invesco S&P MidCap Quality ETF and 4.39% in First Trust NYSE Arca Biotechnology Index Fund [11].

Thematic investors are split between two big future bets: robotics and electric vehicles. But for now, each has a different engine driving it. Robotics is gaining traction with politicians in Washington. Meanwhile, priority attention is still focused on car sales and battery prices for electric cars. This makes a difference to ETF traders. • ROBO Global Robotics and Automation Index ETF stock is under selling pressure. Why are ROBO shares declining?Why Robotics Suddenly Has A Policy TailwindShares related t ...

Group 1 - The ROBO Global Robotics and Automation Index ETF (ROBO) is designed to provide investors with exposure to industrial automation and robotics, offering diverse industry and regional exposure [1] - ROBO has a significant adoption with assets totaling $1.25 billion [1] Group 2 - Michael Del Monte is a buy-side equity analyst with expertise in technology, energy, industrials, and materials sectors, having over a decade of experience in professional services across various industries [1]